SinoMab FY2025 loss narrows 43.3% to RMB105 million, total funding available jumps 148.5% to RMB351 million

Reuters

Yesterday

SinoMab FY2025 loss narrows 43.3% to RMB105 million, total funding available jumps 148.5% to RMB351 million

SinoMab published an annual results announcement for the year ended Dec. 31, 2025, including a change in use of proceeds.
Loss for the year was RMB105.0 million, a 43.3% decrease.
Total funding available to use was RMB351.5 million, more than doubled, reflecting share subscription proceeds and partially offset by bank borrowing repayments, operating cash outflows and capital expenditures.
Net cash used in operating activities was RMB70.48 million, while net cash from financing activities was RMB329.39 million.
Business updates included positive Phase 1b topline results for SM17 in atopic dermatitis, initiation of a Phase 1 bridging study for subcutaneous administration, and NMPA acceptance of an SM17 IND for inflammatory bowel disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260323-12063744), on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2621351704"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621351704\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621351704?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 22:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621351704","market":"fut","top_or_hot":-1,"title":"SinoMab FY2025 loss narrows 43.3% to RMB105 million, total funding available jumps 148.5% to RMB351 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SinoMab FY2025 loss narrows 43.3% to RMB105 million, total funding available jumps 148.5% to RMB351 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          SinoMab published an annual results announcement for the year ended Dec. 31, 2025, including a change in use of proceeds.\n        </li>\n<li>\n          Loss for the year was RMB105.0 million, a 43.3% decrease.\n        </li>\n<li>\n          Total funding available to use was RMB351.5 million, more than doubled, reflecting share subscription proceeds and partially offset by bank borrowing repayments, operating cash outflows and capital expenditures.\n        </li>\n<li>\n          Net cash used in operating activities was RMB70.48 million, while net cash from financing activities was RMB329.39 million.\n        </li>\n<li>\n          Business updates included positive Phase 1b topline results for SM17 in atopic dermatitis, initiation of a Phase 1 bridging study for subcutaneous administration, and NMPA acceptance of an SM17 IND for inflammatory bowel disease.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260323-12063744), on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SinoMab FY2025 loss narrows 43.3% to RMB105 million, total funding available jumps 148.5% to RMB351 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinoMab FY2025 loss narrows 43.3% to RMB105 million, total funding available jumps 148.5% to RMB351 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 22:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SinoMab FY2025 loss narrows 43.3% to RMB105 million, total funding available jumps 148.5% to RMB351 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          SinoMab published an annual results announcement for the year ended Dec. 31, 2025, including a change in use of proceeds.\n        </li>\n<li>\n          Loss for the year was RMB105.0 million, a 43.3% decrease.\n        </li>\n<li>\n          Total funding available to use was RMB351.5 million, more than doubled, reflecting share subscription proceeds and partially offset by bank borrowing repayments, operating cash outflows and capital expenditures.\n        </li>\n<li>\n          Net cash used in operating activities was RMB70.48 million, while net cash from financing activities was RMB329.39 million.\n        </li>\n<li>\n          Business updates included positive Phase 1b topline results for SM17 in atopic dermatitis, initiation of a Phase 1 bridging study for subcutaneous administration, and NMPA acceptance of an SM17 IND for inflammatory bowel disease.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260323-12063744), on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03681","symbol_name":"中国抗体-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL9DY9rX:1","article_id":"2621351704","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621351704","pubTimestamp":1774275473,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SinoMab published an annual results announcement for the year ended Dec. 31, 2025, including a change in use of proceeds.Loss for the year was RMB105.0 million, a 43.3% decrease.Total funding available to use was RMB351.5 million, more than doubled, reflecting share subscription proceeds and partially offset by bank borrowing repayments, operating cash outflows and capital expenditures.Net cash used in operating activities was RMB70.48 million, while net cash from financing activities was RMB329.39 million.Business updates included positive Phase 1b topline results for SM17 in atopic dermatitis, initiation of a Phase 1 bridging study for subcutaneous administration, and NMPA acceptance of an SM17 IND for inflammatory bowel disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03681":"中国抗体-B","BK1574":"生物医药B类股","BK1161":"生物科技"},"translate_title":"Sinomab 2025财年亏损收窄43.3%至人民币1.05亿元，可用资金总额跃升148.5%至人民币3.51亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03681":0.9},"content_text":"SinoMab FY2025 loss narrows 43.3% to RMB105 million, total funding available jumps 148.5% to RMB351 million\n    \n\n\n          SinoMab published an annual results announcement for the year ended Dec. 31, 2025, including a change in use of proceeds.\n        \n\n          Loss for the year was RMB105.0 million, a 43.3% decrease.\n        \n\n          Total funding available to use was RMB351.5 million, more than doubled, reflecting share subscription proceeds and partially offset by bank borrowing repayments, operating cash outflows and capital expenditures.\n        \n\n          Net cash used in operating activities was RMB70.48 million, while net cash from financing activities was RMB329.39 million.\n        \n\n          Business updates included positive Phase 1b topline results for SM17 in atopic dermatitis, initiation of a Phase 1 bridging study for subcutaneous administration, and NMPA acceptance of an SM17 IND for inflammatory bowel disease.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260323-12063744), on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}